Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICMT | O60725 | 2/20 | 0.62 |
| ▸ | CDC25A | P30304 | 1/20 | 0.60 |
| ▸ | DNM2 | P50570 | 4/20 | 0.48 |
| ▸ | CNR2 | P34972 | 6/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5154481 | 1.00 | ICMT (0.62) | ICMTCDC25ADNM2CNR2CNR1 | |
| SCHEMBL5154580 | 0.95 | ICMT (0.55) | ICMTCDC25ADNM2CNR2CNR1 | |
| SCHEMBL5156070 | 0.84 | SCN9A (0.53) | ICMTSCN9A | |
| SCHEMBL4613529 | 0.84 | SCN9A (0.53) | ICMTSCN9A | |
| SCHEMBL5149260 | 0.84 | SCN9A (0.53) | ICMTSCN9A | |
| SCHEMBL4602461 | 0.84 | CCNT1 (0.49) | ICMTCDC25ACNR2CNR1SCN9A | |
| SCHEMBL5151251 | 0.84 | CCNT1 (0.49) | ICMTCDC25ACNR2CNR1SCN9A | |
| SCHEMBL5155397 | 0.82 | SCN9A (0.47) | ICMTCDC25ACNR2CNR1SCN9A | |
| SCHEMBL5462804 | 0.82 | CDC25A (0.70) | ICMTCDC25ADNM2CNR2CNR1 | |
| SCHEMBL5151526 | 0.82 | SCN9A (0.49) | ICMTCDC25ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060573-A1 | Acyltryptophanols | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060573-A1 | Acyltryptophanols | FSHR, NPY1R, NPY2R | ICMT 4467/4885CDC25A 915/4885DNM2 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.